Veru reports positive phase 2 clinical trial results for enobosarm, selective androgen receptor targeting agent, for endocrine resistant metastatic breast cancer

-- phase 2 multicenter, international clinical study selected as spotlight presentation at 2020 san antonio breast cancer symposium –

VERU Ratings Summary

VERU Quant Ranking